Healix

Outpatient Treatment of Infective Endocarditis (IE) at Physician Office Infusion Centers (POICs): A 2-Year Analysis of Clinical and Economic Outcomes

Authors:
Brian S. Metzger, MD, MPH – Austin Infectious Disease Consultants, Austin, TX
Richard M. Mandel, MD, FIDSA – Southern Arizona Infectious Disease Specialists, PLC, Tucson, AZ
Jorge R. Bernett, MD – Infectious Disease Doctors Medical Group, Walnut Creek, CA
Barry Statner, MD, FRCPC, FIDSA -Mazur, Statner, Dutta, Nathan, PC, Thousand Oaks, CA
John S. Adams, MD, FIDSA, FSHEA – Knoxville Infectious Disease Consultants, P.C., Knoxville, TN
Alfred E. Bacon III, MD – Infectious Disease Associates, PA, Newark, DE
Kimberly Couch, PharmD, MA, FIDSA, FASHP – Healix Infusion Therapy, Inc., Sugar Land, TX
Claudia P. Schroeder, PharmD, PhD – Healix Infusion Therapy, Inc., Sugar Land, TX
Lucinda J. Van Anglen, PharmD – Healix Infusion Therapy, Inc., Sugar Land, TX

View Poster View Abstract

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.

FacebookTwitterLinkedInarrow1arcsearchiconowdtnotfound